Irish stent startup nets $17M in financing round
Cappella has completed a $17.3 million series C investment, led by new investors, Fountain Healthcare Partners and Mitsui Venture Partners. Enterprise Ireland also participated in the round alongside Cappella's existing investors, Polytechnos Partners and ACT Venture Capital.
Proceeds will be used to finance the launch of Cappella's Sideguard sidebranch stent for the treatment of bifurcated vascular disease in Europe and to advance research and development programs in Galway, Ireland, on additional applications of Cappella's technology in complex coronary artery disease (CAD), according to the company.
"The funding will allow us to expand our pipeline, to supplement ongoing clinical studies and to successfully launch our first product, the Sideguard sidebranch stent," said Art Rosenthal, MD, Cappella's recently appointed CEO. Rosenthal previously served as chairman and CEO of Labcoat and as chief scientific officer of Boston Scientific.
Cappella was founded in 2004 by Antonio Columbo, MD, chief of invasive cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, MD, PhD, a cardiologist, medical device entrepreneur, with the backing of Polytechnos Venture Partners and ACT Venture Capital.
Proceeds will be used to finance the launch of Cappella's Sideguard sidebranch stent for the treatment of bifurcated vascular disease in Europe and to advance research and development programs in Galway, Ireland, on additional applications of Cappella's technology in complex coronary artery disease (CAD), according to the company.
"The funding will allow us to expand our pipeline, to supplement ongoing clinical studies and to successfully launch our first product, the Sideguard sidebranch stent," said Art Rosenthal, MD, Cappella's recently appointed CEO. Rosenthal previously served as chairman and CEO of Labcoat and as chief scientific officer of Boston Scientific.
Cappella was founded in 2004 by Antonio Columbo, MD, chief of invasive cardiology at San Raffaele Hospital in Milan, Italy, and Ascher Shmulewitz, MD, PhD, a cardiologist, medical device entrepreneur, with the backing of Polytechnos Venture Partners and ACT Venture Capital.